3 documents found, page 1 of 1
Epidemiology and risk factors for hyperkalaemia in heart failure
Grobbee, Diederick E.; Filippatos, Gerasimos; Desai, Nihar R.; Coats, Andrew J. S.; Pinto, Fausto J.; Rosano, Giuseppe M. C.; Cleland, John G. F.Patients with heart failure (HF), particularly those with impaired renal function receiving renin-angiotensin-aldosterone system inhibitors (RAASis), are at risk of hyperkalaemia; when hyperkalaemia is severe, this can have serious clinical consequences. The incidence, prevalence, and risk factors for hyperkalaemia reported in randomized trials of RAASis may not reflect clinical practice due to exclusion of pat...
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgita...
Anker, Stefan D.; Friede, Tim; von Bardeleben, Ralph Stephan; Butler, Javed; Khan, Muhammad Shahzeb; Diek, Monika; Heinrich, Jutta; Geyer, MartinAim: The RESHAPE-HF2 trial is designed to assess the efficacy and safety of the MitraClip device system for the treatment of clinically important functional mitral regurgitation (FMR) in patients with heart failure (HF). This report describes the baseline characteristics of patients enrolled in the RESHAPE-HF2 trial compared to those enrolled in the COAPT and MITRA-FR trials. Methods and results: The RESHAPE-HF...
Patiromer for the management of hyperkalemia in heart failure with reduced ejec...
Butler, Javed; Anker, Stefan D.; Lund, Lars H; Coats, Andrew J. S.; Filippatos, Gerasimos; Siddiqi, Tariq Jamal; Friede, Tim; Fabien, VincentAims: To investigate the impact of patiromer on the serum potassium level and its ability to enable specified target doses of renin-angiotensin-aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF). Methods and results: A total of 1642 patients with HFrEF and current or a history of RAASi-related hyperkalemia were screened and 1195 were enrolled in the run...